Liposome-Mesoporous Silica Nanoparticles Fused Cores: A Safer Mode of Drug Carrier

2011 ◽  
Vol 7 (1) ◽  
pp. 60-62 ◽  
Author(s):  
K. P. Singh ◽  
Preety Panwar ◽  
Pooja Kohli ◽  
. Sanjesh
Keyword(s):  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Mesoporous Silica Nanoparticles ◽  
Drug Carrier

scholarly journals Synthesis of surface capped mesoporous silica nanoparticles for pH-stimuli responsive drug delivery applications

MedChemComm ◽  
2017 ◽  
Vol 8 (9) ◽  
pp. 1797-1805 ◽  
Author(s):  
Madhappan Santha Moorthy ◽  
Subramanian Bharathiraja ◽  
Panchanathan Manivasagan ◽  
Kang Dae Lee ◽  
Junghwan Oh
Keyword(s):  
Drug Delivery ◽  
Cancer Therapy ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Mesoporous Silica Nanoparticles ◽  
Drug Carrier ◽  
Stimuli Responsive ◽  
Ph Responsive ◽  
Drug Delivery Applications

Herein, we propose a “host–guest” complexation-based mesoporous silica drug carrier, MSNs@Mela@TTM, for pH-responsive drug delivery applications in cancer therapy.

scholarly journals Chitosan modified mesoporous silica nanoparticles as a versatile drug carrier with pH dependent properties

2019 ◽  
Author(s):  
Angela Vionna Santoso ◽  
Alex Susanto ◽  
Wenny Irawaty ◽  
Lannie Hadisoewignyo ◽  
Sandy Budi Hartono
Keyword(s):  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Mesoporous Silica Nanoparticles ◽  
Drug Carrier ◽  
Ph Dependent

scholarly journals PEI-PEG-Coated Mesoporous Silica Nanoparticles Enhance the Antitumor Activity of Tanshinone IIA and Serve as a Gene Transfer Vector

2021 ◽  
Vol 2021 ◽  
pp. 1-12
Author(s):  
Yinxing Zhu ◽  
Miao Yue ◽  
Ting Guo ◽  
Fang Li ◽  
Zhifeng Li ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Gene Transfer ◽  
Antitumor Activity ◽  
Mesoporous Silica ◽  
Sustained Release ◽  
Silica Nanoparticles ◽  
Mesoporous Silica Nanoparticles ◽  
Drug Carrier ◽  
Tanshinone Iia

Tanshinone IIA (TanIIA) and gene therapy both hold promising potentials in hepatocellular carcinoma (HCC) treatment. However, low solubility and poor bioavailability of TanIIA limit its clinical application. Similarly, gene therapy with GPC3-shRNA, a type of short hairpin RNAs (shRNAs) capable of silencing the glypican-3 (GPC3) expression, is seriously limited due to its susceptibility to nuclease degradation and high off-target effects. In the present study, polyethyleneimine (PEI)-polyethylene glycol (PEG)-coated mesoporous silica nanoparticles (MSN-PEG) were used as a drug carrier. By encapsulating TanIIA into MSN-PEG, we synthesized MSN-TanIIA-PEG nanoparticles and observed the involved characteristics. This was followed by exploration of antitumor activity on the HepG2 cell lines in vitro. Meanwhile, in order to construct GPC3-shRNA plasmids, a shRNA sequence targeting GPC3 was synthesized and cloned into the pSLenti-U6 vector. Accordingly, the performance of MSN-PEG as a gene transfer carrier for GPC3-shRNA gene therapy of HCC in vitro was evaluated, including transfection efficiency and DNA binding biological characteristics. The results indicated successful encapsulation of TanIIA in MSN-PEG, which had satisfactory efficacy, favorable dispersity, suitable particle size, and sustained release effect. The in vitro anti-HCC effects of nano-TanIIA were greatly improved, which outperformed free-TanIIA in terms of proliferation and invasion inhibition, as well as apoptosis induction of HCC cells. As expected, MSN-PEG possessed excellent gene delivery capacity with good binding, release, and protection from RNase digestion. Using MSN-PEG as a gene carrier, the plasmids were successfully transfected into HepG2 cells, and both the mRNA and protein expressions of GPC3 were significantly downregulated. It was thus concluded that a sustained release TanIIA delivery system for HCC treatment was synthesized and that MSN-PEG could also serve as a gene transfer carrier for gene therapy. More interestingly, MSN-PEG may be a potential delivery platform that combines TanIIA and GPC3-shRNA together to enhance their synergistic effect.

scholarly journals Costunolide Loaded in pH-Responsive Mesoporous Silica Nanoparticles for Increased Stability and an Enhanced Anti-Fibrotic Effect

2021 ◽  
Vol 14 (10) ◽  
pp. 951
Author(s):  
Xia Niu ◽  
Xiaomei Wang ◽  
Bingyu Niu ◽  
Yanan Meng ◽  
Hongwei He ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Dissolution Rate ◽  
Mesoporous Silica Nanoparticles ◽  
Drug Carrier ◽  
Public Health Problem ◽  
Great Promise ◽  
Ph Responsive ◽  
Bile Duct Proliferation

Liver fibrosis remains a significant public health problem. However, few drugs have yet been validated. Costunolide (COS), as a monomeric component of the traditional Chinese medicinal herb Saussurea Lappa, has shown excellent anti-fibrotic efficacy. However, COS displays very poor aqueous solubility and poor stability in gastric juice, which greatly limits its application via an oral administration. To increase the stability, improve the dissolution rate and enhance the anti-liver fibrosis of COS, pH-responsive mesoporous silica nanoparticles (MSNs) were selected as a drug carrier. Methacrylic acid copolymer (MAC) as a pH-sensitive material was used to coat the surface of MSNs. The drug release behavior and anti-liver fibrosis effects of MSNs-COS-MAC were evaluated. The results showed that MSNs-COS-MAC prevented a release in the gastric fluid and enhanced the dissolution rate of COS in the intestinal juice. At half the dose of COS, MSNs-COS-MAC still effectively ameliorated parenchymal necrosis, bile duct proliferation and excessive collagen. MSNs-COS-MAC significantly repressed hepatic fibrogenesis by decreasing the expression of hepatic fibrogenic markers in LX-2 cells and liver tissue. These results suggest that MSNs-COS-MAC shows great promise for anti-liver fibrosis treatment.

Stimuli-responsive delivery vehicles based on mesoporous silica nanoparticles: recent advances and challenges

2017 ◽  
Vol 5 (7) ◽  
pp. 1339-1352 ◽  
Author(s):  
Jianhua Zhu ◽  
Yimin Niu ◽  
Yang Li ◽  
Yaxiang Gong ◽  
Huihui Shi ◽  
...  
Keyword(s):  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Mesoporous Silica Nanoparticles ◽  
Drug Carrier ◽  
Stimuli Responsive ◽  
Drug Delivery Vehicles ◽  
The Past ◽  
Functionalized Mesoporous Silica ◽  
New Type ◽  
Delivery Vehicles

In the past decade, stimuli-responsive drug delivery vehicles based on surface-functionalized mesoporous silica nanoparticles have attracted intense interest as a new type of drug carrier.

scholarly journals Synthesis of Hydrophobic and Hydrophilic Loaded Mesoporous Silica Nanoparticles for Controlled Co-Delivery of Drugs

2021 ◽  
Author(s):  
PRIYADHARSINI K ◽  
ANBUCHEZHIYAN M ◽  
SANGEETHA K ◽  
SENGUTTUVAN N ◽  
RAJENDRAN SRIBA
Keyword(s):  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Mesoporous Silica Nanoparticles ◽  
Drug Carrier ◽  
Hexagonal Structure ◽  
X Ray Diffraction ◽  
Transmission Electron ◽  
Bet Analysis ◽  
Uv Visible ◽  
Dual Drug

Abstract Herein, a biocompatible and nontoxicity novel type of hydrophobic and hydrophilic co-delivery systems based on co-polymer chitosan-graft-PMMA (ch-g-PMMA) modified Mesoporous silica nanoparticles (MSNPs) for cancer therapy was prepared. The pores of MSNPs were loaded with curcumin (CUR) and doxorubicin (DOX) with co-polymer ch-g-PMMA were gated the pores of MSNPs to prevent the release of drugs. These synthesized ch-g-PMMA/MSNPs dual drug-loaded are effectively allowed for co-delivery of drug combinations with improved efficacy. The dual drug loaded MSNPS were characterized by X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FTIR), UV-Visible spectroscopy (UV-Vis), Transmission electron microscope (TEM) and Brunauer–Emmett–Teller (BET) analysis. The TEM and XRD results proved the successful loading of drugs into the pores of hexagonal structure MSNPs with size ~180nm, CUR and DOX were released from the MSNPs only in acid –triggered manner. The cytotoxicity studied were carried out for ch-g-PMMA/MSNPs dual drug-loaded against adenocarcinoma gastric cell line (AGS) shows that MSNPs was highly biocompatible and well suitable for drug carrier.

Sign in / Sign up

Export Citation Format

Share Document